Abstract
Introduction There is paucity of studies done to assess the composition and staining quality of Romanosky-type stains used for malaria microscopy in Nigeria.
Methods We conducted a cross-sectional study among 92 laboratory facilities and subjected them to UV-spectroscopy, HPLC, GC, ashing and pH measurement. We conducted multivariable binary logistic regression analysis at p<0.05.
Result Of 94 stains, 38(40.4%) were Field, 36(38.3%) were Giemsa, and 20(21.3%) were Leishman stains. Overall, 23.7%, 33.3% and 25.0% of Field, Giemsa and Leishman stains respectively yielded satisfactory staining. Predictors of staining quality were proportion of Azure B>20% (aOR = 15.1, 95% CI = 2.62-115.00); Azure B to Eosin Y ratio >1.5 (aOR = 4.55, 95% CI = 1.03-25.10); and alcoholic solvent (aOR = 27.70, 95% CI = 2.43-462.00).
Conclusion Romanowsky-type stains used for malaria microscopy in Plateau State were of variable composition and mostly lacked the RGE-relevant dyes required for good nuclear and cytoplasmic differentiation of malaria parasites.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was purely funded out-of-pocket.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the University of Ibadan/University College Hospital Ethics Committee (Ref:UI/EC/17/0352), Plateau State Ethical Review Committee (Ref: MOH/MIS/202/VOL.T/X), Plateau State Hospitals Management Board (ADM/554/vol.1/141) and Jos University Teaching Hospital Ethics Committee (Ref: JUTH/DCS/ADM/127/XXVII/704).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We revised the abstract and references of the previous version of the manuscript to conform with the abstract requirement of Life Epidemiology and Global Health. We intend to submit this version to Life for publication.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
